United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 Shares

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $929,678.52. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Michael Benkowitz also recently made the following trade(s):

• On Tuesday, February 18th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00.
• On Monday, February 10th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00.
• On Monday, February 3rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $353.64, for a total transaction of $3,536,400.00.
• On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $370.71, for a total transaction of $3,707,100.00.
• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.62, for a total transaction of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $356.68, for a total value of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $361.95, for a total value of $3,619,500.00.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded down $0.71 during trading on Tuesday, hitting $357.50. 590,905 shares of the stock were exchanged, compared to its average volume of 368,414. The firm’s 50-day moving average price is $362.39 and its 200 day moving average price is $360.91. The stock has a market cap of $15.96 billion, a price-to-earnings ratio of 15.70, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 12-month low of $221.53 and a 12-month high of $417.82.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on UTHR. LADENBURG THALM/SH SH increased their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. HC Wainwright boosted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Argus raised their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $388.25.

Institutional Trading of United Therapeutics

A number of institutional investors have recently bought and sold shares of UTHR. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics during the 4th quarter worth about $25,000. Brooklyn Investment Group acquired a new stake in United Therapeutics during the third quarter worth approximately $33,000. Dunhill Financial LLC raised its holdings in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 50 shares in the last quarter. State of Wyoming purchased a new stake in shares of United Therapeutics during the 4th quarter worth approximately $62,000. Finally, Millstone Evans Group LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at $67,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.